Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

22.2%

6 terminated/withdrawn out of 27 trials

Success Rate

76.0%

-10.5% vs industry average

Late-Stage Pipeline

22%

6 trials in Phase 3/4

Results Transparency

21%

4 of 19 completed trials have results

Key Signals

4 with results6 terminated

Enrollment Performance

Analytics

Phase 2
4(40.0%)
Phase 4
4(40.0%)
Phase 3
2(20.0%)
10Total
Phase 2(4)
Phase 4(4)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (27)

Showing 20 of 27 trials
NCT02682641Phase 2Active Not Recruiting

Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL

Role: collaborator

NCT03207282Completed

Treatment Resistant Depression in America Latina

Role: lead

NCT02692248Phase 2Completed

Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT

Role: collaborator

NCT04476446Phase 3Completed

An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives

Role: lead

NCT05527340Phase 2Not Yet Recruiting

Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.

Role: collaborator

NCT03685500Phase 4Completed

A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c)

Role: collaborator

NCT03042390Completed

Study of the Effectiveness and Safety of Darunavir/Cobicistat (DRV/c) Containing Regimens in Routine Clinical Practice

Role: collaborator

NCT01848132Phase 2Completed

Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.

Role: collaborator

NCT02414984Terminated

Registry for Analysis of Compliance in Colombian Participants With Rheumatoid Arthritis Exposed to Golimumab

Role: lead

NCT00639054Completed

The Molecular Characterization of Multiple Myeloma at Relapse

Role: collaborator

NCT01181921Phase 4Terminated

The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease

Role: lead

NCT00358852Completed

Scale Validation Study for Prediction of Relapse and Short Term Rehospitalization in Patients With Schizophrenia

Role: lead

NCT01867164Phase 3Completed

A Study to Compare Efficacy and Safety of an Ovule Containing Terconazole, Clindamycin and Fluocinolone Versus an Ovule Containing Metronidazole, Nystatin and Fluocinolone in the Treatment of Secondary Vulvar/ or Vaginal Symptoms of Infectious Vaginitis/ and Infectious Vaginosis

Role: lead

NCT01262534Completed

A Study to Assess the Clinical Profile of Patients in Spain With Moderate to Severe Psoriasis.

Role: lead

NCT01724359Phase 4Completed

Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Patients With Schizophrenia

Role: lead

NCT01376492Completed

FYS Study: Epidemiological, Multicentre, Cross-sectional Study in a Clinical Practice Environment, About the Relationship Between Functioning Status and the Quality of Sleep Perceived by Schizophrenic Outpatients in Spain

Role: lead

NCT01402830Completed

Case-control Study- Cancer Pain: Uncontrolled Pain as Depression Development Predictor in Oncologic Patients (Fentanyl)

Role: lead

NCT01478204Completed

A Study to Evaluate Sleep Quality in Patients With Mild to Moderate Alzheimer's Disease

Role: lead

NCT01309373Completed

An Epidemiological Study to Assess the Psychosocial and Symptomatic Remission and Community Integration Status in Patients With Schizophrenia

Role: lead

NCT00511966Terminated

Influence of Hygiene-dietetic Habits and Treatment Adherence on the Effectiveness of the Gastroesophageal Reflux Illness Treatment With Rabeprazol

Role: lead